We are live on ! Find out more

Kenvue

KVUE

Market cap $34.2B

17.78 USD

-0.01

0.06%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

17.79

+0.01

0.06%

1 day

-0.06%

5 days

-5.68%

1 month

-6.67%

3 months

-1.6%

6 months

0.74%

Year to date

2.66%

1 year

-5.68%

5 years

-33.9%

10 years

-33.9%

About: Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Employees: 22,000

Consumer Staples Household & Personal Products

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 38.9%

Neutral 33.3%

Negative 27.8%

Kenvue Declares Quarterly Cash Dividend

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson.

Kenvue Declares Quarterly Cash Dividend

Zacks Investment Research

Kenvue's Brand Strength and Innovation Strategy Support Growth

KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.

American Century Value Fund Q2 2026 Contributors And Detractors

U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Key contributors include Infineon Technologies, Teradyne and Walmart. Key detractors include Micron Technology, Intel and Sandisk.

American Century Value Fund Q2 2026 Contributors And Detractors

Zacks Investment Research

Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?

Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.

Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?

Zacks Investment Research

Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead

KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.

Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead

Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment

Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree ‌and Stayfree period care brands in the country to address competition concerns.

Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment

Best Dividend Aristocrats For September 2026

Dividend Aristocrats, tracked via NOBL, delivered a 12.9% YTD return, closely trailing SPY's 13.68%, with 29 Aristocrats outperforming SPY in 2026. Top 2026 performers include TGT (+73.04%), NUE (+55.64%), and BEN (+49.25%), highlighting strong sectoral momentum among select Aristocrats. Six Aristocrats announced dividend increases in the past month, pushing the group's average 2026 dividend growth rate to 4.30%, up from 4.10% last month.

Best Dividend Aristocrats For September 2026

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover ‌of Tylenol maker Kenvue, documents on the EU Commission's website showed.

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Best Dividend Kings: August 2026

Dividend Kings are outperforming the S&P 500 YTD, with a 14.98% total return versus SPY's 12.89%. Thirty Dividend Kings are beating SPY, and 25 appear both potentially undervalued and offer ≥10% annualized return potential. Dividend growth among Kings accelerated, with the average rate rising to 4.12% and several notable increases announced.

Best Dividend Kings: August 2026

Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel

Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Jeff Melucci, Chief Strategy, Business Development and Administrative Officer, and will become a member of Kimberly-Clark's Executive Leadership Team.

Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel

See News Rankings

Price charts implemented using Lightweight Charts™